Put companies on watchlist
Boston Scientific
ISIN: US1011371077
WKN: 884113
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Boston Scientific · ISIN: US1011371077 · PR Newswire (ID: 20241002NE21051)
02 October 2024 02:00PM

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results


-Company to also host virtual webcast with a cardiology business update-

MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.

The company will also host a virtual investor event on Wednesday, October 30, 2024, from 4:00 – 5:00 p.m. ET following Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). Joe Fitzgerald, executive vice president and president of Cardiology, Dr. Ken Stein, executive vice president and global chief medical officer, Lance Bates, executive vice president and president Interventional Cardiology Therapies (ICTx) and Dr. Janar Sathananthan, chief medical officer ICTx, will present a business update and answer questions from investors.

A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.  

CONTACTS:

Chanel Hastings

Media Relations

+1 (508) 382-0288

Chanel.Hastings@bsci.com

Jon Monson

Investor Relations

+1 (508) 683-5450

BSXInvestorRelations@bsci.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-conference-call-discussing-third-quarter-2024-results-302265174.html

SOURCE Boston Scientific Corporation

Visual performance / price development - Boston Scientific
Smart analysis and research tools can be found here.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942